ConductScience.org, home

Paper41454396

Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances.

Fatahichegeni M and 5 others. J Transl Med, 2025. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances. Papers, record 41454396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41454396

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances.
PubMed
Journal
J Transl Med
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
2.19, provisional
iCite
Revised in PubMed
2026-09-10
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fatahichegeni MMahsa
2Ansarian MAMohammad Aminhttps://orcid.org/0009-0007-5511-4717
3Wang YYuqi
4Ren JJuan
5Zhang TTongxin
6Wang XXiaoning

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Neurotoxicity SyndromesMajor topic
Immunotherapy, AdoptiveMajor topic
Receptors, Chimeric AntigenMajor topic
T-LymphocytesMajor topic
Humans
Animals

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
National Key R&D Program, Grant/Award Number: 2022YFC2502700National Key R&D Program, Grant/Award Number: 2022YFC2502700PubMed

Source PubMed

Download CSV of grants

References67

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136531846Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy.Neurohospitalist2023https://conductscience.org/library/papers/36531846PubMed
238300610Two years later: CD19 CAR-T going the distance.Blood2024https://conductscience.org/library/papers/38300610PubMed
340650909CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients.Cell Rep2025https://conductscience.org/library/papers/40650909PubMed
436860569A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome.Front Neurol2023https://conductscience.org/library/papers/36860569PubMed
536593069CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses.J Immunother Cancer2023https://conductscience.org/library/papers/36593069PubMed
633985527Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy.Cancer Cell Int2021https://conductscience.org/library/papers/33985527PubMed
733599849Correction to: ICU-outcomes in CAR-T patients-A single centre experience.Intensive Care Med Exp2021https://conductscience.org/library/papers/33599849PubMed
838203814The Mechanisms of Altered Blood-Brain Barrier Permeability in CD19 CAR T-Cell Recipients.Int J Mol Sci2024https://conductscience.org/library/papers/38203814PubMed
936989488How I treat refractory CRS and ICANS after CAR T-cell therapy.Blood2023https://conductscience.org/library/papers/36989488PubMed
1037345104Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia.Cancers (Basel)2023https://conductscience.org/library/papers/37345104PubMed
1132327504Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma.Haematologica2021https://conductscience.org/library/papers/32327504PubMed
1236414694EEG-based grading of immune effector cell-associated neurotoxicity syndrome.Sci Rep2022https://conductscience.org/library/papers/36414694PubMed
1339567446Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model.EJNMMI Res2024https://conductscience.org/library/papers/39567446PubMed
1436763238CAR-T Cell Therapy: the Efficacy and Toxicity Balance.Curr Hematol Malig Rep2023https://conductscience.org/library/papers/36763238PubMed
1535216966Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill.Med Intensiva (Engl Ed)2022https://conductscience.org/library/papers/35216966PubMed
1632271898Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial.Blood Adv2020https://conductscience.org/library/papers/32271898PubMed
1735094839[Management of neurotoxicity following CAR-T cell therapy: Recommendations of the SFGM-TC].Bull Cancer2023https://conductscience.org/library/papers/35094839PubMed
1839474369Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis.Front Neurol2024https://conductscience.org/library/papers/39474369PubMed
1935000613Neurological management and work-up of neurotoxicity associated with CAR T cell therapy.Neurol Res Pract2022https://conductscience.org/library/papers/35000613PubMed
2034794490Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.J Exp Clin Cancer Res2021https://conductscience.org/library/papers/34794490PubMed

See all 67 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42953552Neurologist-focused workflows for immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy and CD3-engaging bispecific antibodies.Front Neurol2026https://conductscience.org/library/papers/42953552PubMed
42921052When, Where, and How Much: Toward Smarter Design and Delivery of CAR T‑Cell Therapy.ACS Bio Med Chem Au2026https://conductscience.org/library/papers/42921052PubMed
42865900B7-H3-mediated immune regulation in cancer: biological functions and therapeutic opportunities.Front Pharmacol2026https://conductscience.org/library/papers/42865900PubMed
42840927Microbiota-derived metabolic priming of CAR-T cell fitness: a translational framework for next-generation cell therapy.Front Immunol2026https://conductscience.org/library/papers/42840927PubMed
42592017Endotheliopathy in CAR T-Cell Therapy: Mechanistic Insights into the VWF/ADAMTS13 Axis and the Angiopoietin-Tie2 Pathway.TH Open2026https://conductscience.org/library/papers/42592017PubMed
42590834Targeted delivery of mRNA to immune cells for in vivo cell therapy.Drug Deliv2026https://conductscience.org/library/papers/42590834PubMed
42548674Critical complications in cancer patients admitted to the ICU in the era of immunotherapy: recognition, differential diagnosis, and management.Front Med (Lausanne)2026https://conductscience.org/library/papers/42548674PubMed
42345736Quality of Life in CAR-T Cell Therapy.Hematol Rep2026https://conductscience.org/library/papers/42345736PubMed
42286319Reprogramming immunity: the promise and challenges of CAR T cell therapy in multiple sclerosis.Inflammopharmacology2026https://conductscience.org/library/papers/42286319PubMed
42109668Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study.Front Oncol2026https://conductscience.org/library/papers/42109668PubMed
42108277T-Cell Immunosenescence in Systemic Lupus Erythematosus: Molecular Mechanisms and Therapeutic Perspectives.Clin Rev Allergy Immunol2026https://conductscience.org/library/papers/42108277PubMed
41928252In vivo CAR-T therapy: from molecular design to precision delivery.J Nanobiotechnology2026https://conductscience.org/library/papers/41928252PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41454396

GET https://conductscience.org/api/papers/v1/41454396/references?page=2